Home - Marinus Pharmaceuticals

Mindful Innovation

Marinus is developing ganaxolone to improve the lives of
patients with epilepsy and neuropsychiatric disorders

CNS Solutions

Ganaxolone offers a new mechanism of action and is
designed with selectivity and safety in mind

Offering Continuity of Care

GANAXOLONE

The Right Treatment | The Right Formulation
A Wide Range of Conditions

Marinus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company dedicated to the development of ganaxolone, which offers a new mechanism of action, an extensive safety database, and convenient dosing to improve the lives of patients suffering from drug-resistant seizures and neuropsychiatric disorders.

Press Releases

Marinus Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference

Sep 21, 2017

Marinus Pharmaceuticals Announces closing of Public Offering of Common Stock and full exercise of underwriter's option to purchase additional shares

Sep 19, 2017

Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Sep 15, 2017

More Press Releases >

Events

Cantor Fitzgerald's Global Healthcare Conference

Click for Additional Information

9/27/17

Child Neurology Society

10/4/17 - 10/7/17

Clinical Trials

Physicians and patients learn more about ganaxolone and Marinus Pharmaceuticals’ clinical trials here.

View Pipeline >

Follow Us on Twitter

4 hours ago

Marinus Pharma
@MarinusPharma

Marinus Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference. Press release:… t.co/IUl7dsdLMq